Related Experiment Video
Updated: May 31, 2026
Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment
Published on: November 23, 2017
Effects of altered plasminogen activator inhibitor-1 expression on cardiovascular disease
1W M Keck Center for Transgene Research and Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana, USA. vploplis@nd.edu
Insights
Plasminogen activator inhibitor-1 (PAI-1) plays a dual role in cardiovascular disease, impacting both blood clotting and cell signaling. Understanding its complex functions is key to developing effective treatments.
Area of Science:
- Biochemistry
- Molecular Biology
- Cardiovascular Research
Background:
- Plasminogen activator inhibitor-1 (PAI-1) is a key regulator of fibrinolysis and cell signaling.
- Elevated PAI-1 levels are linked to cardiovascular disease development and progression.
- PAI-1's precise role in disease is complex, with studies showing both protective and detrimental effects.
Purpose of the Study:
- To explore the multifaceted roles of PAI-1 in cardiovascular disease.
- To review current understanding of PAI-1's impact on fibrinolysis and cell signaling.
- To discuss therapeutic strategies targeting PAI-1.
Main Methods:
- Review of existing literature on PAI-1 function and its role in cardiovascular disease.
- Analysis of studies using PAI-1 deficient mouse models.
- Examination of pharmacological and lifestyle interventions affecting PAI-1.
Main Results:
- PAI-1's dual role in regulating fibrinolysis and cell signaling contributes to its ambiguous function in disease.
- Evidence suggests PAI-1 can both promote and inhibit various disease states.
- Interventions targeting PAI-1's function in plasmin formation have been studied in thrombosis models.
Conclusions:
- Further research into PAI-1's regulation of cell function is needed to resolve paradoxical findings.
- Targeting PAI-1's cell signaling pathways may offer novel therapeutic approaches for cardiovascular disease.
- A comprehensive understanding of PAI-1's complex roles is crucial for effective disease management.
Abstract:
Plasminogen Activator Inhibitor-1 (PAI-1) is a multifunctional protein with the ability to not only regulate fibrinolysis through inhibition of plasminogen activation, but also cell signaling events which have direct downstream effects on cell function. Elevated plasma levels of this protein have been shown to have profound effects on the development and progression of cardiovascular diseases. However, results from a number of studies, especially those using PAI-1 deficient mouse models, have demonstrated that its function is ambiguous, with evidence of both preventing and enhancing various disease states. A number of lifestyle changes and pharmacological reagents have been identified that can regulate PAI-1 levels or function. Those reagents that target function are focused on its ability to regulate plasmin formation, and have been studied in in vivo models of thrombosis. Further investigations involving regulation of cell function could potentially resolve paradoxical issues associated with the function of this protein in regulating cardiovascular disease.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Peripheral Artery Disease I: Introduction
01:16Clot Retraction and Fibrinolysis
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu